In this article, we are going to take a look at where Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) stands against other most oversold healthcare stocks to buy now. Healthcare costs and spending ...

In a report released today, Graig Suvannavejh from Mizuho Securities maintained a Hold rating on Apellis Pharmaceuticals (APLS – Research Report), with a price target of $30.00. See what stocks ...

In this article, we are going to take a look at where Apellis Pharmaceuticals (NASDAQ:APLS) stands against other top insider stock buys and sells in January. Ever heard of the “January effect?” ...

Swedish Orphan Biovitrum AB (Sobi) (OTC:SWOBY) (OTC:BIOVF) and Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) on Thursday ...

In a report released on February 28, Lisa Walter from RBC Capital maintained a Hold rating on Apellis Pharmaceuticals (APLS – Research Report), with a price target of $25.00. The company’s ...

Short interest in Apellis Pharmaceuticals Inc (NASDAQ:APLS) increased during the last reporting period, rising from 17.06M to 17.34M. This put 19.09% of the company's publicly available shares short.